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Purpose
Gastric cancer is the third-leading cause of cancer-related death in Korea. As the Korean
population is ageing, the number of extremely old patients with this disease is increasing.
This study examined the clinicopathological characteristics of gastric cancer in extremely
old (over 85 years) patients who received treatment or conservative observations and com-
pared the treatment outcomes according to the treatment modality. 
Materials and Methods
A total of 170 patients over 85 years of age were diagnosed with gastric cancer. Of these,
81 underwent treatment for gastric cancer and 89 received conservative observations. The
clinicopathological characteristics of the treatment and conservative groups were compared. 
Results
The mean age of the patients was 86.5 years. The conservative group included significantly
more patients with older ages, macroscopically advanced cancer and upper-middle located
cancer. The overall survival rate of the treatment group was significantly higher than that of
the conservative group. The disease-specific mortality rate was significantly lower in the
treatment group than in the conservative group. Multivariate analysis revealed the clinical
course, alarm sign, and macroscopic classification to be independent prognosis factors.
Conclusion
By itself, the chronological age should not be used as a strategy to determine whether treat-
ment will be administered for gastric cancer. Patients who have early gastric cancer or lower-
risk preexisting comorbidities should not be discouraged from treatment, even if they are
older than 85 years.
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Introduction
Following thyroid cancer, gastric cancer (GC) is the second
most common cancer in Korea [1]. Recently, as the Korean
society is aging, there has been an increasing number of eld-
erly patients diagnosed with GC. Despite this, there is little
data available on the clinicopathological characteristics of GC
in elderly patients, particularly in those who are very elderly.
In Korea, the life expectancy is more than 80 years and the
most common cause of death is cancer [2]. According to the
statistics released by Statistics Korea, approximately 12% of
cancer-related deaths have been caused by GC in recent
years. Although the 5-year survival rate of GC has been 
increasing over the past two decades due to early detection
by screening endoscopy [3], little is known about GC screen-
ing in the very elderly. 
Endoscopic treatment is the accepted standard treatment
for selected cases of GC. The safety of endoscopic treatment
is comparable to surgery in elderly patients [4-8]. Endoscopic
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resections (ERs) are also performed on elderly patients with
comorbid heart and lung diseases [9]. Therefore, the strategy
of GC treatment varies in elderly patients with age-associ-
ated comorbidities. Age is a clinically important factor for
determining the treatment modality [10], and clinicians are
often cautious when managing elderly patients with GC 
because of their age-related performance status [11-13].
This study investigated the clinicopathological character-
istics of GC in extremely old (over 85 years) patients who 
received treatment or conservative observations. In addition,
the treatment outcomes were compared according to the
treatment modality. 
Materials and Methods
1. Patients 
From June 1998 to July 2014, a total of 358 patients over 85
years old were diagnosed with GC at Severance Hospital
(Seoul, Korea). For the present analysis, the following 
patients were excluded (1) those who had no subsequent fol-
low-up visits after diagnosis, (2) those who had a significant
comorbidity that could affect the mortality, and (3) those
who had been treated at another hospital during the follow-
up period. Of the 358 patients, 188 were excluded and the 
remaining 170 were enrolled. The patients were evaluated in
terms of their general information, such as age, sex, and treat-
ment method. The variables investigated also included the
macroscopic classification, histological classification, comor-
bidity, postoperative mortality, and clinical outcome. As cat-
egorized by the treatment modality for GC, 81 patients
underwent treatment (treatment group), such as an endo-
scopic resection, surgery, chemotherapy, or radiotherapy,
and 89 patients received conservative observation (conserv-
ative group). The staging of the patients in the conservative
group could not be evaluated accurately. Therefore, the 
patients were divided roughly into two groups: those with
macroscopically early GCs (cancer confined to the mucosa
or submucosa) and those with macroscopically advanced GC
(cancer with invasion extending through the muscularis pro-
pria). The patients’ medical records were reviewed retrospec-
tively. The Institutional Review Board (IRB) of Severance
Hospital approved this study (IRB approval number: 4-2014-
0464).
2. Statistical analysis
The chi-square test and Fisher exact test were used to com-
pare the clinicopathological characteristics between the treat-
ment-modality groups. Follow-up data on all patients were
obtained from the Korea National Health Insurance Service
database. The median follow-up period was 17.8 months
(range, 0.1 to 172.4 months). The survival curves were esti-
mated using the Kaplan-Meier method. The accepted signif-
icant level was p < 0.05. All statistical analyses were perfor-
med using SPSS ver. 20.0 for Windows (IBM Co., Armonk,
NY).
Results
1. Clinicopathological characteristics 
The sex or histologic type was similar in the two groups.
On the other hand, older age, macroscopically advanced can-
cer, and upper-middle located cancer were significantly
more common in the conservative group (Table 1). In the
treatment group, 21 patients underwent ER, 48 patients 
underwent gastrectomy, and 12 patients underwent chemo-
therapy or radiotherapy. Of the 21 patients who received ER,
20 had lesions included in the absolute indication and one
patient had lesions included in the expanded indication. Of
the 48 patients who received surgery, 46 underwent a cura-
tive gastric resection (subtotal gastrectomy, n=43; total gas-
trectomy, n=3) and two received palliative gastrectomy. The
curative resection rate was 18/21 (85.7%) for ER and 46/48
(95.8%) for gastrectomy. In the conservative observation
group, 38/89 patients (42.7%) refused the recommended
treatment. 
In the overall study cohort, the most common concomitant
disease was hypertension (32.9%). Eighty-two patients
(48.2%) had one or more comorbid diseases and 37 patients
(21.8%) had more than two comorbid diseases.
One hundred forty-three patients (84.1%) visited the hos-
pital with symptoms and 27 patients (15.9%) were diagnosed
with GC during a health check-up. The most common initial
presentation was abdominal pain, which was present in 69
patients (40.6%). Thirty-seven patients (21.8%) had alarm
signs (weight loss, signs and symptoms of upper gastroin-
testinal bleeding, and anemia), and the presence of an alarm
sign was significantly more common in the conservative 
observation group than in the treatment group. On the other
hand, indigestion was significantly more common in the
treatment group.
2. Clinical outcomes
A postoperative complication (bleeding) occurred in one
patient who underwent a gastrectomy; this patient died three
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days after surgery. No other procedure-related complications
were observed in the patients who received ER. Recurrence
developed in two of the patients who received ER. One 
patient had a local recurrence and the other patient devel-
oped liver metastasis. Eight of the patients who underwent
surgery experienced a recurrence.
3. Survival 
The overall survival rate in the treatment group was sig-
nificantly higher than that in the conservative group 
(Fig. 1A). Furthermore, the disease-specific mortality was
significantly lower in the treatment group than in the con-
Table 1. Clinicopathological characteristics of the treatment and conservative observation groups
Factor Treatment group Conservative group p-value(n=81) (n=89)
Age (yr) 85.9±1.9 87.1±2.6
Range 85.0-94.0 85.0-96.0 0.003
Sex
Male 58 (71.6) 53 (59.6) 0.109
Female 23 (28.4) 36 (40.4)
Macroscopic classification
Early 34 (42.0) 12 (13.5) < 0.001
Advanced 47 (58.0) 77 (86.5)
Histologic type
Differentiated 55 (67.9) 58 (65.2) 0.747
Undifferentiated 26 (32.1) 31 (34.8)
Location
Upper 5 (6.2) 22 (24.7) 0.001
Middle 23 (28.4) 30 (33.7)
Lower 53 (65.4) 35 (39.3)
Unknown 0 ( 2 (2.2)
Tumor size (cm) 4.63±3.42 4.64±2.44 0.981
Distant metastasis
Absence 74 (91.4) 50 (56.2) < 0.001
Presence 7 (8.6) 25 (28.1)
Unknown 0 ( 14 (15.7)
Concomitant disease
None 40 (49.4) 48 (53.9) 0.645
Hypertension 28 (34.6) 28 (31.5) 0.744
Cardiovascular disease 5 (6.2) 3 (3.4) 0.481
Diabetes mellitus 13 (16.0) 11 (12.4) 0.516
Cerebral infarction 13 (16.0) 3 (3.4) 0.007
Chronic pulmonary disease 2 (2.5) 4 (4.5) 0.684
Chronic kidney disease 1 (1.2) 2 (2.2) > 0.99
Other malignancy 3 (3.7) 7 (7.9) 0.335
Initial presentation
Abdominal pain 30 (37.0) 39 (43.8) 0.435
Indigestion 21 (25.9) 10 (11.2) 0.017
Hematemesis 4 (4.9) 9 (10.1) 0.255
Melena 2 (2.5) 8 (9.0) 0.103
Hematochezia 2 (2.5) 0 (0.0) 0.226
Anemia 1 (1.2) 7 (7.9) 0.068
General weakness 1 (1.2) 5 (5.6) 0.215
Weight loss 2 (2.5) 2 (2.2) > 0.99
None 18 (22.2) 9 (10.1) 0.037
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
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servative group (Fig. 1B). The 81 patients in the treatment
group and the 89 patients in the conservative group were 
divided into early GC and advanced GC subgroups, as
shown in Fig. 2. For the patients with advanced GC, the over-
all survival rate was significantly higher in the treatment
group than in the conservative group. For patients with early
GC, the overall survival rate was also significantly higher in
the treatment group than in the conservative group 
(p < 0.001) (Fig. 2A). Similarly, the disease-specific mortality
in the treatment group was significantly lower than that in
the conservative group, regardless whether early or 
advanced GC had been diagnosed (p < 0.001) (Fig. 2B). Sub-
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Fig. 1. (A) Overall survival rate of the treatment (n=81) and conservative (n=89) groups. (B) Disease-specific mortality of the
treatment (n=81) and conservative (n=89) groups.  
Su
rv
iva
l r
at
e 
(%
)
1.0
0.8
0.6
0.4
0.2
0
0
Time (mo)
4020 60 80 120100 140
A
Early, treatment
Early, conservative
Advanced, treatment
Advanced, conservative
p < 0.001
Early, treatment
Early, conservative
Advanced, treatment
Advanced, conservative
p < 0.001D
ise
as
e-
sp
ec
ifi
c 
m
or
ta
lit
y r
at
e 
(%
)
1.0
0.8
0.6
0.4
0.2
0
0
Time (mo)
4020 60 80 120100 140
B
Fig. 2. The patients in the treatment group and the conservative group were divided into early gastric cancer (GC) and 
advanced GC subgroups (early and treatment group, n=34; early and conservative group, n=12; advanced and treatment
group, n=47; and advanced and conservative group, n=77). (A) Overall survival rate with GC patients showing macroscopic
classification and clinical course. (B) Disease-specific mortality rate with GC patients showing macroscopic classification and
clinical course. 
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group analysis was performed on the overall survival and
disease specific mortality between the conservative observa-
tion group who refused the recommended treatment and the
treatment group. The overall survival rate of the treatment
group was significantly higher than the conservative obser-
vation group who refused the recommended treatment and
the disease specific mortality rate was significantly lower
(Fig. 3). The patients in the treatment group and the conser-
vative observation group who refused the recommended
treatment were divided into early GC and advanced GC sub-
groups. The overall survival rate was significantly higher
and the disease-specific mortality rate was significantly
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Fig. 3. (A) Overall survival rate of the treatment (n=81) and conservative (n=38) groups refused recommended treatment.
(B) Disease-specific mortality of the treatment (n=81) and conservative (n=89) groups refused recommended treatment.  
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Fig. 4. The patients in the treatment group and the conservative group refused recommended treatment were divided into
early gastric cancer (GC) and advanced GC subgroups (early and treatment group, n=34; early and conservative group, n=9;
advanced and treatment group, n=47; and advanced and conservative group, n=29). (A) Overall survival rate with GC 
patients showing macroscopic classification and clinical course. (B) Disease-specific mortality rate with GC patients showing
macroscopic classification and clinical course. 
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lower in the treatment group than in the conservative obser-
vation group who refused the recommended treatment, 
regardless whether early or advanced GC had been diag-
nosed (Fig. 4). In addition, the survival according was eval-
uated to treatment modality. The overall survival rate of the
ER and surgery group was similar and the disease-specific
mortality of the ER and surgery group was also similar (data
not shown).
4. Effects of clinicopathological characteristics on progno-
sis
Seven factors (clinical course, age, sex, histologic type,
macroscopic classification, alarm sign, and concomitant dis-
ease) were evaluated by univariate analyses to investigate
the associations of the clinicopathological characteristics with
the prognosis. Significant differences were observed for the
clinical course (p < 0.001), age (p=0.027), histologic type
(p=0.031), alarm sign (p < 0.001), and macroscopic classifica-
tion (p < 0.001) (Table 2). The same seven factors were then
Table 2. Correlation between the prognostic factors and the survival rates of 170 gastric cancer patients
Factor No. 3-Yr p-valuesurvival rate (%)
Clinical course
Treatment group 81 50.7 < 0.001
Conservative observation 89 16.8
Age (yr)
< 90 150 35.0 0.027
 90 20 26.4
Sex
Male 111 32.8 0.525
Female 59 36.1
Histologic type
Differentiated 113 37.0 0.031
Undifferentiated 57 27.0
Macroscopic classification
Early 46 68.1 < 0.001
Advanced 124 21.4
Alarm sign
Absence 133 38.3 < 0.001
Presence 37 15.8
Concomitant disease
Absence 88 29.4 0.344
Presence 82 38.6
Table 3. Multivariate analysis of the prognosis factors for mortality
Factor Odds ratio (95% CI) p-value
Clinical course (conservative observation vs. treatment group) 2.7 (1.7-4.2) < 0.001
Age ( 90 yr vs. < 90 yr) 1.0 (0.5-1.8) 0.997
Sex (male vs. female) 1.0 (0.7-1.5) 0.941
Histology (undifferentiated vs. differentiated) 1.4 (0.9-2.1) 0.107
Macroscopic classification (advanced vs. early) 2.4 (1.4-4.1) 0.001
Comorbidity (presence vs. absence) 0.8 (0.6-1.2) 0.283
Alarm sign (presence vs. absence) 1.9 (1.2-3.0) 0.009
CI, confidence interval.
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analyzed by multivariate analysis, which revealed the clini-
cal course (p < 0.001), alarm sign (p=0.009), and macroscopic
classification (p < 0.001) to be independent prognosis factors
(Table 3).
Discussion
As the society ages, clinicians are increasingly being con-
fronted with the challenges of treating elderly patients. In
Korea, the number of patients diagnosed with GC at 
extremely old ages has been increasing [1]. Several reports
have shown that older patients tend to receive less treatment
for GCs than younger patients [14-18]. When clinicians make
the decision to treat cancer, they consider the cancer stage,
the patient’s performance status, deterioration of the 
patient’s mental status, and concomitant disease together;
they do not rely on the patient’s age alone. Generally, the
prognosis of elderly patients has been thought to be worse
than that of younger patients because of concomitant disease.
On the other hand, deaths due to other concomitant diseases
amounted to 34%-37% of the total deaths in > 80-year-old 
patients with GC [11,19]. Matsushita et al. [20] investigated
patients with GC who were older than 80 years and reported
that the survival rate after surgical treatment was signifi-
cantly higher than that for conservative observation, regard-
less of the patient’s performance status and irrespective of
whether his or her mental status had deteriorated. The
macroscopic classification of the case (e.g., early or advanced
cancer) was an important prognostic factor. Therefore, they
recommended surgical treatment for patients older than 80
years [20]. Treatments are recommended for GC, even for
older patients with age-associated comorbidities that are
under control [21]. In a study of the natural history of early
GC, Tsukuma et al. [22] reported that the cumulative 5-year
risk for progression to an advanced stage was 63.0%. Even
patients with early GC usually die within 3 years in the 
absence of treatment [20]. On the other hand, Katai et al. [23]
reported that when a gastrectomy had been performed safely
by specialists, the survival rate of elderly patients with early
GC was not significantly different from that of the general
population. Therefore, the treatment of early GC should not
be discouraged in very elderly patients. In this study, 
patients in the treatment group, those with early GC, and
those without an alarm sign showed higher overall survival
rates than the others. 
Currently, ER is widely accepted as a standard treatment
for early GC [24]. Compared to gastrectomy, ER is a less 
invasive treatment for GC and has many advantages. These
advantages include preservation of the stomach, which 
increases the quality of life and reduces the length of hospi-
talization compared to gastrectomy. Furthermore, ER-related
complications result from the difficulties encountered when
performing the resection endoscopically, which are associ-
ated with the tumor size and location, rather than age [6,8].
Several reports have shown that ER is a safe and feasible
treatment for GC in elderly patients [5,6,8]. Etoh et al. [25] 
reported that the results of an endoscopic mucosal resection
in patients older than 80 years were outstanding, and were
the same as those obtained via gastrectomy. Therefore, eld-
erly patients with earlier-stage cancer should receive less-
invasive treatments. As the techniques of preoperative and
perioperative management have improved, the outcomes of
gastric surgery in the elderly have also shown favorable 
results [23,26]. Therefore, treatment should not be discour-
aged for elderly patients with GC. Similarly, the overall sur-
vival rate of the patients in the present study’s treatment
group was significantly higher than that in the conserva-
tively observed group. 
In this study, advanced GC accounted for 72.9% of cases.
The percentage of patients with advanced cancer was signif-
icantly higher in the conservative observation group than in
the treatment group. Advanced-stage cancers were a cause
of the poor prognosis. Therefore, it is important to recognize
cancers at the earlier stage to provide a better prognosis in
elderly patients. In a previous study, the prevalence of pre-
existing concomitant disease was significantly higher in eld-
erly patients [8]. In the present study, 88 patients (51.8%) did
not have any concomitant disease. Furthermore, 143 patients
(84.1%) presented with symptoms and 37 patients (21.8%)
showed an alarm sign. In addition, patients with an alarm
sign had advanced-stage cancers. Therefore, elderly patients
who are being followed up for concomitant disease also need
to be checked for gastrointestinal disease. When patients
have symptoms, the clinicians need to consider further eval-
uations. 
This study had some limitations. This study was retrospec-
tive and could not investigate exactly how the decision was
made as to whether to treat the patients or not. In addition,
the TNM classification of the patients could not be evaluated
because the staging of the patients in the conservative group
could not be investigated accurately. In this study, however,
the overall survival of the patients with advanced GC was
significantly lower than in the early GC. Furthermore, the
macroscopic classification was an independent prognosis
factor in multivariate analysis.
Cancer Res Treat. 2017;49(1):204-212
210 CANCER  RESEARCH  AND  TREATMENT
Conclusion
Chronological age alone should not be used as a strategy
of determining if treatment will be administered for GC. 
Patients with early GC or lower-risk preexisting comorbidi-
ties should not be discouraged from treatment, even if they
are older than 85 years.
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